Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06582888 · ClinicalTrials.gov registry record · Early Phase 1
Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder
A Early Phase 1 study of Nicotine Addiction and Craving, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06582888: Recruiting Early Phase 1 study of Nicotine Addiction and Craving, sponsored by University of California, San Diego.
NCT06582888 is a Early Phase 1 study of Nicotine Addiction and Craving that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 200 participants, below the 704-participant average among 10 other Nicotine Addiction trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06582888, a Early Phase 1 study of Nicotine Addiction and Craving, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed project will include enrollment of 200 daily tobacco cigarette users, ages 22+, from the San Diego community. Participants will be assessed on the VR Nicotine Cue Exposure paradigm then randomized (stratified on age and sex) to receive varenicline (target dose 1mg twice daily) or placebo (n per group=100; total N=200). Following eight days of titration, participants will be assessed again on the VR Nicotine Cue Exposure paradigm. They will then be followed via mobile assessments for eight days on target dose of varenicline, and 30-days post assessment by phone, to assess short-term nicotine use behaviors.
Primary Outcome
Eye gaze fixation time to active versus neutral cues from the \"NTP Cue VR Paradigm\"
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Varenicline Tartrate
Study Locations (1)
California
- University California, San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-11-19 |
| Est. Completion | 2028-08-15 |
| Phase | Early Phase 1 |
What NCT06582888 shows while recruiting
NCT06582888 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 704-participant average among 10 other Nicotine Addiction trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Nicotine Addiction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06582888 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06582888 about?
NCT06582888 is a clinical study titled "Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder". The proposed project will include enrollment of 200 daily tobacco cigarette users, ages 22+, from the San Diego community. Participants will be assessed on the VR Nicotine Cue Exposure paradigm then randomized (stratified on age and sex) to receive varenicline (target dose 1mg twice daily) or placeb...
What is the current status of trial NCT06582888?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 200 participants. The study started on 2024-11-19. Estimated completion is 2028-08-15.
What conditions does trial NCT06582888 study?
This clinical trial studies the following conditions: Nicotine Addiction, Craving.
What interventions are being tested in trial NCT06582888?
The interventions under investigation include: Placebo (DRUG), Varenicline Tartrate (DRUG).
Who is sponsoring clinical trial NCT06582888?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06582888 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Addiction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06582888's enrollment target sits among peer trials
200 5th of 10 higher than 6 of 10 other Nicotine Addiction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nicotine Addiction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Product Characteristics on the Abuse Liability of Nicotine Pouches
RECRUITING · NA
-
CONNECT Cancer Survivors With Tobacco Treatment
RECRUITING · NA
-
Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)
RECRUITING · NA
-
Cognitive Training for Nicotine Dependence
COMPLETED · NA
-
Effects of Brief Training on Craving Regulation
COMPLETED · NA
-
Acute and Chronic Nicotine Modulation of Reinforcement Learning
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI